7.67
전일 마감가:
$7.69
열려 있는:
$7.66
하루 거래량:
3.96M
Relative Volume:
1.02
시가총액:
$794.46M
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-1.3996
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
-20.60%
1개월 성능:
-13.24%
6개월 성능:
-47.07%
1년 성능:
-67.01%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NTLA
Intellia Therapeutics Inc
|
7.67 | 1.00B | 45.97M | -508.80M | -382.65M | -5.48 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2025-03-05 | 개시 | H.C. Wainwright | Buy |
2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
2024-02-15 | 개시 | Wolfe Research | Peer Perform |
2023-04-13 | 개시 | Canaccord Genuity | Buy |
2023-03-21 | 개시 | Bernstein | Outperform |
2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2022-10-11 | 개시 | Morgan Stanley | Overweight |
2022-09-21 | 개시 | JP Morgan | Overweight |
2022-09-01 | 개시 | Citigroup | Sell |
2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
2022-06-16 | 개시 | BofA Securities | Buy |
2022-04-28 | 개시 | Credit Suisse | Outperform |
2022-02-18 | 개시 | William Blair | Outperform |
2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
2022-01-31 | 개시 | Cowen | Outperform |
2022-01-07 | 개시 | Piper Sandler | Overweight |
2021-10-05 | 개시 | Guggenheim | Buy |
2021-09-24 | 개시 | Stifel | Buy |
2021-06-28 | 재확인 | H.C. Wainwright | Buy |
2021-06-11 | 개시 | H.C. Wainwright | Buy |
2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-10-27 | 개시 | Truist | Buy |
2020-10-14 | 개시 | Wells Fargo | Overweight |
2020-09-18 | 개시 | Goldman | Buy |
2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2019-07-09 | 개시 | Robert W. Baird | Outperform |
2019-06-10 | 개시 | ROTH Capital | Neutral |
2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
2019-04-12 | 개시 | Evercore ISI | Outperform |
2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
2018-10-29 | 개시 | Credit Suisse | Neutral |
2018-09-21 | 개시 | Raymond James | Mkt Perform |
2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
2017-11-01 | 재확인 | Jefferies | Buy |
2017-06-22 | 재개 | Jefferies | Buy |
2017-03-28 | 개시 | Chardan Capital Markets | Buy |
2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter
Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus
Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar
ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus
Intellia adverse event could resurface questions, says JPMorgan - TipRanks
Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus
Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha
Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN
Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com
Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks
Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
Intellia commercial position in question after safety event. says Goldman - TipRanks
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus
Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria
Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech
Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus
H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga
Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India
Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada
Intellia stock tumbles on safety concerns - Investing.com
Intellia stock down on safety concern for gene editing drug - Seeking Alpha
Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com
NTLA: Intellia Therapeutics Advances Key Clinical Trials | NTLA Stock News - GuruFocus
BofA cuts Intellia stock target to $39, maintains Buy rating By Investing.com - Investing.com India
Intellia stock holds after JMP reiterates market perform - Investing.com Australia
Intellia stock holds after JMP reiterates market perform By Investing.com - Investing.com India
Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study - TipRanks
Intellia reports progress in Phase 3 clinical trials - Investing.com
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):